Work Files Saved Searches
   My Account                                                  Search:   Quick/Number   Boolean   Advanced   Derwent    Help   


 The Delphion Integrated View
  Buy Now:   Buy PDF- 9pp  PDF  |   File History  |   Other choices   
  Tools:  Citation Link  |  Add to Work File:    
  View:  Expand Details   |  INPADOC   |  Jump to: 
  Go to:  Derwent  
 Email this to a friend  Email this to a friend 
       
Title: US5721104: Screening assay for anti-HIV drugs
[ Derwent Title ]

Country: US United States of America

View Images High
Resolution

 Low
 Resolution

 
9 pages

 
Inventor: Chen, Irvin S. Y.; Woodland Hills, CA
Jowett, Jeremy B. M.; Los Angeles, CA
Planelles, Vicente; Los Angeles, CA

Assignee: Regents of the University of California, Los Angeles, CA
other patents from UNIVERSITY OF CALIFORNIA, THE REGENTS OF (599425) (approx. 4,840)
 News, Profiles, Stocks and More about this company

Published / Filed: 1998-02-24 / 1995-06-07

Application Number: US1995000485694
IPC Code: Advanced: C07K 14/16; C12N 1/19; C12N 5/10; C12N 15/09; C12P 21/02; G01N 33/15; G01N 33/50; A61K 38/00; C12R 1/91;
Core: C07K 14/005; more...
IPC-7: G01N 33/53; G01N 33/567;

ECLA Code: G01N33/50D2B; C07K14/16F; G01N33/50D2; G01N33/50D2D2; K61K38/00; M07K203/00; M07K207/00; S01N333/16F; S01N500/00; M12N740/03F;

U.S. Class: Current: 435/007.1; 435/007.2; 435/007.21;
Original: 435/007.1; 435/007.2; 435/007.21;

Field of Search: 435/7.2,7.21,7.1

Government Interest:

ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT
    The work described herein was funded in part by a grant from the National Institutes of Health No. C930122. The U.S. government has certain rights in this invention.

Priority Number:
1995-06-07  US1995000485694
1994-10-13  US1994000322750

Abstract:     The essential role of the Vpr protein of HIV in the progression of HIV infection is disclosed. Recognition of this role permits assay for potential drug candidates by virtue of their ability to interfere with the interaction of Vpr with its intracellular targets. Thus, cells that are modified to contain an expression system for the production of Vpr are cultured in the presence and absence of the drug candidate and the growth rates compared. The ability of a candidate to enhance the growth of a culture producing Vpr indicates its potential as an anti-AIDS therapeutic.

Attorney, Agent or Firm: Morrison & Foerster LLP ;

Primary / Asst. Examiners: Hendricks, Keith D.;

Maintenance Status: CC Certificate of Correction issued

INPADOC Legal Status: Show legal status actions          Buy Now: Family Legal Status Report

       
Related Applications:
Application Number Filed Patent Pub. Date  Title
US1994000322750 1994-10-13       


       
Parent Case:     This application is a continuation of application Ser. No. 08/322,750 filed 13 Oct. 1994.

Designated Country: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  AU CA EP JP 

Family: Show 8 known family members
First Claim:
Show all 6 claims		 We claim:     1. A method to identify a compound that blocks Vpr mediated cell cycle statis, said method comprising the steps of:
  • a) contacting a compound to be tested with a Vpr protein;
  • b) determining whether said compound binds to said Vpr protein;
  • c) identifying a compound that binds to said Vpr protein;
  • d) culturing cells in the presence and absence of said compound of step (c), said cells having been modified to contain an expression system that encodes a Vpr protein, under conditions in which the Vpr protein is expressed and blocks cell division;
  • e) measuring an indicator of cell replication of the cells that were cultured in the presence and absence of said compound;
  • f) identifying a compound that can block HIV mediated cell cycle arrest by selecting a compound in which cell replication in the presence of said compound is greater than in the absence of said compound.
    •


Background / Summary: Show background / summary

Drawing Descriptions: Show drawing descriptions

Description: Show description

Forward References: Show 3 U.S. patent(s) that reference this one

       
U.S. References: Go to Result Set: All U.S. references   |  Forward references (3)   |   Backward references (0)   |   Citation Link

       
Foreign References:
Buy
PDF		 Publication Date IPC Code Assignee   Title
Buy PDF- 46pp WO9119817 1991-12  C12N 5/10 DANA FARBER CANCER INSTITUTE EXPRESSION VECTORS CONTAINING THE HIV (NEF) GENE TO ENHANCE REPLICATION EFFICIENCY 
Buy PDF- 115pp WO9419456 1994-09  A61K 38/00 LEVY, David, Nathan VPR FUNCTION AND ACTIVITY 
Buy PDF- 115pp WO9419456 1994-09  A61K 38/00 LEVY, David, Nathan VPR FUNCTION AND ACTIVITY 


Other Abstract Info: CHEMABS 125(07)076327G DERABS C1996-221753

Other References:
  • Balotta, C., Antisense Phosphorothioate Oligodeoxynucleotides Targeted to the vpr Gene Inhibit Human Immunodeficienc Virus Type 1 Replication in Primary Human Macrophages, J. Virol (1993) 67:4409. (6 pages) Cited by 15 patents [ISI abstract]
  • Cohen, E.A. et al. Identification of HIV-1 vpr Product and Function, J AIDS (1990) 3:11-18. (8 pages) Cited by 18 patents
  • Cohen, E.A. et al. Human Immunodeficiency Virus vpr Product Is a Virion-Associated Regulatory Protein, J Virol (1990) 64:3097-3099. (3 pages) Cited by 23 patents
  • Gras-Masse, H. et al. A Synthetic Protein Corresponding to the Entire vpr Gene Product from the Human Immunodeficiency virus HIV-1 is Recognized by Antibodies from HIV-Infected Patients, Int J Pept Prot Res (1990) 36:219. (8 pages) Cited by 11 patents
  • Hattori, N. et al. The Human Innumodeficiency Virus Type 2 vpr Gene is Essential for Productive Infection of Human Macrophages, Proc Natl Acad Sci USA (1990) 87:8080-8084. (5 pages) Cited by 23 patents
  • Heinzinger, N.K. et al. The Vpr Protein of Human Immunodeficiency Virus Type 1 Influences Nuclear Localizatioin of Viral Nucleic Acids in Nondividing Host Cells, Proc Natl Acad Sci USA (1994) 91:7311-7315. (5 pages) Cited by 31 patents [ISI abstract]
  • Lang, S.M. et al. Importance of vpr for Infection of Rhesus Monkeys with Simian Immunodeficiency Virus, J Virol (1993) 67:902-912. (11 pages) Cited by 10 patents [ISI abstract]
  • Lavallee, C. et al. Requirements of the Pr55gag Precursor for Incorporation of the Vpr Product into Human Immunodeficiency Virus Type 1 Viral Particles, J Virol (1994) 68:1926. (9 pages) Cited by 14 patents [ISI abstract]
  • Levy, D.N. et al. Induction of Cell Differentiation by Human Immunodeficiency Virus 1 vpr, Cell (1993) 72:541. (10 pages) Cited by 32 patents [ISI abstract]
  • Ogawa, K. et al. Open Reading Frame J Virol (1990) 63:4110-4114.
  • Paxton, W. et al. Incorporation of Vpr into Human Immunodeficiency Virus Type 1 Virions: Requirement for the p6 Region of gag and Mutational Analysis, J Virol (1993) 67:7229-7237. (9 pages) Cited by 14 patents [ISI abstract]
  • Pianelles et al., Manuscript: "Vpr-Induced Cell Cycle Arrest is Conserved Among Primate Lentiviruses", University of Alabama at Birmingham, Division of Hematology and Oncology (date not available).
  • Reiss, P. et al. Antibody Response to Viral Proteins U (vpu) and R (vpr) in HIV-1-Infected Individuals, J AIDS (1990) 3:115. (8 pages) Cited by 9 patents
  • Tristem, M. et al. Evolution of the Primate Lentiviruses: Evidence form vpx and vpr, EMBO J (1992) 11:3405. (8 pages) Cited by 9 patents [ISI abstract]
  • Yu, et al. Open Reading Frame vpr of Simian Immunodeficiency Virus Encodes a Virion-Associated Protein, J Virol (1990) 64:5688. (6 pages) Cited by 20 patents
  • Yuan et al., AIDS Research and Human Retroviruses, vol. 6, No. 11, issued 1990, "Human Immunodeficiency Virus vpr Gene Encodes a Virion-Associated Protein", pp. 1265-1271. (7 pages) Cited by 20 patents


    • Inquire Regarding Licensing

    Powered by Verity
    Plaques from Patent Awards      Gallery of Obscure PatentsNominate this for the Gallery...

    Thomson Reuters Copyright © 1997-2010 Thomson Reuters 
    Subscriptions  |  Web Seminars  |  Privacy  |  Terms & Conditions  |  Site Map  |  Contact Us  |  Help